Targets › TNFRSF18
4 programs from 4 companies in 8 trials: 4 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.
Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. (UniProt, Q9Y5U5)
Open in Phaseline: the race on TNFRSF18, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Belrestotug GITR agonist antibody | TNFRSF18 | Phase 3 | Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Neoplasms | Nov 2026 |
| University of Pennsylvania | Ragifilimab (INCAGN01876) Tumor necrosis factor receptor superfamily member 18 agonist | TNFRSF18 | Phase 2 | Glioblastoma | Apr 2029 |
| Genmab | GEN1042 Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format | CD40, TNFRSF18 | Phase 1 | Malignant Solid Tumor | Jan 2027 |
| Providence Health & Services | Ragifilimab (INCAGN01876) Tumor necrosis factor receptor superfamily member 18 agonist | TNFRSF18 | Phase 1 | Cancer of the Head and Neck | Dec 2027 |
Malignant Solid Tumor (2) Lung Cancer, Non-Small Cell (2) Glioblastoma (1) Cancer of the Head and Neck (1) Neoplasms, Head and Neck (1) Neoplasms (1)
mixed (2), small molecule (1), antibody (1)
University of Pennsylvania (1) Genmab (1) Providence Health & Services (1) GSK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.